Preferred Label : glucagon-like peptide 1;

MeSH definition : A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.;

MeSH synonym : glp-1; glp 1; glucagon like peptide 1; Glucagon-Like Peptide-1;

Registry Number MeSH : 89750-14-1;

Is substance : O;

Details


Main resources

You can consult :

A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.

https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-novembre-2023-23-26-octobre
2023
false
false
false
France
French
drug information
risk assessment
thyroid neoplasms
glucagon-like peptide 1
hypoglycemic agents
GLP-1 Mimetics
Glucagon-like peptide-1 (GLP-1) analogues

---
https://ansm.sante.fr/actualites/creation-dun-comite-scientifique-temporaire-pour-analyser-lusage-des-analogues-du-glp-1
2023
false
false
false
France
French
drug utilization
drug utilization review
GLP-1 Mimetics
Glucagon-like peptide-1 (GLP-1) analogues
glucagon-like peptide 1
Off-Label use
drug information

---
https://sfar.org/mise-au-point-traitement-du-diabete-agonistes-recepteurs-glp1-et-anesthesie/
2023
France
scientific and technical information
GATA-Type Zinc Finger Protein 1
Point Name
anesthesia
diabetes mellitus
lack of sensation
Diabetes Therapy
GCG wt Allele
FBXW4 wt Allele
Benzocaine
CDISC SDTM Diabetes Therapy Terminology
Point
Histone-Lysine N-Methyltransferase EHMT1
Glucagon-like Peptide-1 Measurement
No Treatment for Diabetes
glucagon-like peptide 1
receptors, opioid, mu
ZGLP1 wt Allele
Anesthesia Procedure
Receptor

---
https://pharmacomedicale.org/component/zoo/item/agonistes-du-recepteurs-au-glp1
2022
France
drug information
glucagon-like peptide 1
receptors, opioid, mu

---
https://www.minerva-ebp.be/FR/Article/2237
2021
false
false
false
Belgium
critical appraisal or critical reading
Adult
body weight
semaglutide
Diabetes
diabetes mellitus
exercise
glucagon-like peptide 1
dietetics
association
adulthood
nutritionists
measures
Adult
semaglutide
overweight
glucagon-like peptide 1
adult
diabetes mellitus, nos
weights and measures

---
https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/ressources/reco_sfd_surveillance_glycemique_mars2017.pdf
2018
false
false
false
France
French
blood glucose self-monitoring
glucagon-like peptide 1
practice guideline
patient education as topic
Glucagon-like peptide-1 (GLP-1) analogues
injections, subcutaneous
GLP-1 Mimetics
Capillary blood glucose measurement (procedure)
Capillary specimen collection (procedure)
acetone
acetone
diabetes mellitus
continuity of patient care
ketosis
ketosis
diabetes mellitus
blood glucose
quality control
insulin
Insulin lipohypertrophy (disorder)
Subcutaneous injection of insulin (procedure)
Subcutaneous injection of insulin (procedure)
Insulin administration assessment (procedure)
questionnaires
Initiation of first time insulin therapy (regime/therapy)

---
https://www.revmed.ch/RMS/2017/RMS-N-565/Association-des-analogues-du-GLP-1-et-des-inhibiteurs-du-SGLT2-de-nouvelles-perspectives
2018
false
false
false
Switzerland
French
journal article
administration, oral
hypoglycemic agents
diabetes mellitus, type 2
switzerland
treatment outcome
body weight
cardiovascular diseases
drug therapy, combination
GLP-1 Mimetics
glucagon-like peptide 1
Glucagon-like peptide-1 (GLP-1) analogues
SGLT2 Inhibitor
Sodium-Glucose transporter 2
dulaglutide
Liraglutide
empagliflozin
dapagliflozin
Canagliflozin
blood glucose
arterial pressure
genetic pleiotropy
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
peptides
venoms
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
benzhydryl compounds
glucosides
Exenatide

---
https://medicalforum.ch/fr/detail/doi/fms.2016.02684/
2016
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
practice guidelines as topic
glucagon-like peptide 1
GLP-1 Mimetics
GLP-1 Mimetics
dipeptidyl-peptidase iv inhibitors
cardiovascular diseases
obesity
Sodium-Glucose transporter 2
SGLT2 Inhibitor
SGLT2 Inhibitor
insulins
risk factors
weight loss
hypoglycemia
insulins
hypoglycemic agents
Sodium-Glucose Transporter 2 Inhibitors

---
Summary Basis of Decision (SBD) for Eperzan
Albiglutide 30 mg/0.5 mL and 50 mg/0.5 mL, powder for solution, subcutaneous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00285
2016
false
false
false
false
Canada
French
English
rGLP-1 protein
rGLP-1 protein
injections, subcutaneous
drug approval
canada
summary of product characteristics
treatment outcome
diabetes mellitus, type 2
adult
incretins
incretins
drug therapy, combination
drug evaluation
risk assessment
pregnancy
breast feeding
albiglutide
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1

---
http://www.riziv.fgov.be/SiteCollectionDocuments/consensus_litterature_resume_20161117.pdf
2016
false
false
false
Belgium
French
GLP-1 Mimetics
diabetes mellitus, type 2
review of literature
consensus
GLP-1 Mimetics
treatment outcome
albiglutide
albiglutide
Glucagon-like peptide-1 (GLP-1) analogues
drug therapy, combination
metformin
hypoglycemic agents
hypoglycemic agents
glimepiride
dulaglutide
dulaglutide
Liraglutide
Liraglutide
Sitagliptin Phosphate
sulfonylurea compounds
comparative effectiveness research
arterial pressure
insulin
thyroid neoplasms
pancreatitis
Injection Site Reaction
cardiovascular diseases
practice guidelines as topic
Evidence-Based medicine
rGLP-1 protein
rGLP-1 protein
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
peptides
venoms
peptides
venoms
thiazolidinediones
Pioglitazone
Exenatide
Exenatide

---
http://www.revmed.ch/RMS/2015/RMS-N-477/Analogues-du-GLP-1-versus-inhibiteurs-du-SGLT-2-pour-les-diabetiques-de-type-2-obeses
2015
false
false
false
Switzerland
French
diabetes mellitus, type 2
obesity
comparative effectiveness research
treatment outcome
incretins
hypoglycemic agents
Liraglutide
glucagon-like peptide 1
Canagliflozin
Sodium-Glucose transporter 2
SGLT2 Inhibitor
dapagliflozin
empagliflozin
1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol
other blood glucose lowering drugs, excl. insulins
GLP-1 Mimetics
journal article
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
peptides
venoms
sorbitol
sorbitol
Exenatide

---
http://www.revmed.ch/RMS/2014/RMS-N-439/Interet-d-une-combinaison-agoniste-des-recepteurs-du-GLP-1-et-insuline-basale-dans-le-traitement-du-diabete-de-type-2
2014
false
false
false
Switzerland
French
journal article
drug therapy, combination
hypoglycemic agents
diabetes mellitus, type 2
insulin
treatment outcome
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
incretins
drug combinations
blood glucose
gastric emptying
injections, subcutaneous
Delayed-Action preparations
hyperglycemia, postprandial
semaglutide
rGLP-1 protein
body weight
Liraglutide
Glucagon-Like Peptide-1 Receptor
lixisenatide
hyperglycemia
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
peptides
venoms
glucagon-like peptide 1
glucagon-like peptide 1
Exenatide

---
http://www.revmed.ch/RMS/2014/RMS-N-433/Traitement-combine-d-insuline-et-d-analogue-du-GLP-1-qu-en-attendre
2014
false
false
false
Switzerland
French
journal article
drug therapy, combination
diabetes mellitus, type 2
insulin
hypoglycemic agents
glucagon-like peptide 1
weight gain
insulin
treatment outcome
Glycated Hemoglobin
injections, subcutaneous
diabetes mellitus, type 2

---
http://www.ssmg.be/images/ssmg/files/RMG/312/RMG312_06-12.pdf
2014
false
false
false
Belgium
French
journal article
diabetes mellitus, type 2
insulins
injections
pregnancy in diabetics
hypoglycemic agents
glucagon-like peptide 1
general practice
general practitioners

---
https://www.inspq.qc.ca/sites/default/files/publications/1566_medsysthormonalcanicules.pdf
2012
false
Canada
French
corticosteroid therapy
Ezetimibe
extreme heat
risk factors
administration, oral
hypoglycemic agents
quebec
Drug-Related side effects and adverse reactions
hypolipidemic agents
population characteristics
Bibliographies as Topic
thyroid hormones
renal insufficiency
glyburide
iodine radioisotopes
mineralocorticoids
bromocriptine
insulin
dehydration
alpha-Glucosidases
alpha glucosidase inhibitors
guidelines for drug use
practice guideline
biguanides
biguanides
dipeptidyl peptidase 4 (DPP-4) inhibitors
dipeptidyl-peptidase iv inhibitors
glucagon-like peptide 1
water-electrolyte imbalance
niacin
nicotinic acid
bile acid sequestrants
fibrates
fibric acids
hmg coa reductase inhibitors
hydroxymethylglutaryl-coa reductase inhibitors
ezetimibe
anion exchange resins
reports and studies
thyroid hormones
diphosphonates
imidazoles
Zoledronic Acid

---
http://www.prescrire.org/Fr/101/325/47324/0/PositionDetails.aspx
2011
false
false
false
France
French
drug information
hypoglycemic agents
administration, oral
Drug-Related side effects and adverse reactions
metformin
sulfonylurea compounds
saxagliptin
blood glucose lowering drugs, excl. insulins
Sitagliptin Phosphate
Liraglutide
glucagon-like peptide 1
glucagon-like peptide 1
peptides
venoms
adamantane
adamantane
nitriles
pyrrolidines
dipeptides
Exenatide
Vildagliptin

---
https://www.revmed.ch/RMS/2009/RMS-206/Role-et-place-des-analogues-du-GLP-1-dans-le-traitement-du-diabete-de-type-2
2009
false
Switzerland
French
Liraglutide
Glucagon-Like Peptide-1 Receptor
exenatide
liraglutide
diabetes mellitus, type 2
glucagon-like peptide 1
Product containing glucagon-like peptide 1 receptor agonist (product)
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
hypoglycemic agents
peptides
venoms
journal article
Exenatide
incretins

---
https://www.amub-ulb.be/system/files/rmb/old/369
2007
false
Belgium
French
Sitagliptin Phosphate
Liraglutide
glucagon-like peptide 1
dipeptidyl-peptidase iv inhibitors
diabetes mellitus, type 2
glucagon-like peptide 1
glucagon-like peptide 1
gastric inhibitory polypeptide
gastric inhibitory polypeptide
glucagon-like peptide 1
enzyme inhibitors
hypoglycemic agents
nitriles
adamantane
pyrrolidines
DPP4 protein, human
other blood glucose lowering drugs, excl. insulins
Product containing glucagon-like peptide 1 receptor agonist (product)
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
journal article
drug information
Exenatide
Vildagliptin
peptides
venoms
dipeptidyl peptidase 4
incretins

---
http://revmed.ch/RMS/2007/RMS-122/32497
2007
false
Switzerland
French
Sitagliptin Phosphate
diabetes mellitus, type 2
injections, subcutaneous
administration, oral
dipeptidyl-peptidase iv inhibitors
glucagon-like peptide 1
hypoglycemic agents
peptides
venoms
hypoglycemic agents
glucagon-like peptide 1
dipeptidyl peptidase 4 (DPP-4) inhibitors
other blood glucose lowering drugs, excl. insulins
peptides
venoms
journal article
drug information
Exenatide

---
http://revmed.ch/RMS/2007/RMS-114/32350
2007
Switzerland
French
diabetes mellitus, type 2
glucagon-like peptide 1
incretins
dipeptidyl-peptidase iv inhibitors
journal article

---
Nous contacter.
14/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.